HOME >> MEDICINE >> NEWS
Acrux completes enrollment in key phase 2 trial

Melbourne, Australia, 2 May 2007: Drug delivery company Acrux (ASX: ACR), announced today that it has successfully completed enrolment of 40 patients in the final Phase 2 trial of its unique testosterone lotion for treatment of testosterone deficiency in men. Preliminary results of the trial are expected to be available in July 2007.

The trial is being conducted at 8 clinics in the USA. The aim is to demonstrate that discreet daily application of Acrux's user-friendly lotion to the armpits raises the level of testosterone into the normal range. This is being undertaken by measuring testosterone levels in the blood and does not require the measurement of clinical symptoms.

A Phase 3 trial in 150-200 patients will be required before marketing applications can be made to regulatory authorities. This trial is expected to commence in early 2008 and will again require the measurement of testosterone levels in the blood, rather than the impact on clinical symptoms.

Acrux CEO Richard Treagus commented "Our Phase 2 study will complete on time and the remaining requirements to get this compelling product on the market are relatively straightforward. Confidence in the value of our Testosterone MD-Lotion has been further boosted by the interest shown in this product by potential licensing partners."

About Acrux's Testosterone MD-Lotion

Market research in the USA amongst both patients and prescribers that use current testosterone replacement products, including gels and injections, showed a strong preference by the patients for daily application of Acrux's lotion over the existing products. The Acrux product will apply a precise dose of quick-drying lotion to the armpit once daily, via a convenient and ergonomic "no-touch" applicator.

The leading gel is applied each day as a 5 gram dose by hand to the shoulders, upper arms and/or abdomen. It takes longer to dry and patients are advised
'"/>

Contact: Richard Treagus
richard.treagus@acrux.com.au
61-417-520-509
Research Australia
1-May-2007


Page: 1 2

Related medicine news :

1. Acrux and Oreganon further expand their collaboration
2. Acrux granted first grant in Europe, triggering payment from Lilly
3. Acrux patent portfolio advances in USA
4. Acrux acquires rights to commercialise worlds first contraceptive spray
5. Four new us patents granted to Acrux for transdermal drug delivery
6. Acrux reports progress in development of Testosterone MD-Lotion(R) for men
7. Asthmatx completes enrollment in pivotal study of bronchial thermoplasty
8. MacroChem completes patient enrollment for Phase II trial of EcoNail for treatment of onychomycosis
9. GroPep completes final milestone of the path malaria vaccine initiative
10. Im a Kid Too project completes first phase
11. Worlds largest respiratory health study launches next phase

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a missionary ... Journey: From the Mountains to the Mission Field” is the creation of published author, ... ages and currently teaches a class of ladies at her church, which she has ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... introduction of an innovative new design of the shoulder pad. The shoulder pad ... comfort while controlling your pain while using cold therapy. By utilizing ice and water ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided an update ... Puerto Rico , where the company manufactures ... Following a comprehensive onsite assessment, the ... temporary loss of power and minimal water damage due ... have resumed, and the company expects to return to ...
(Date:10/7/2017)...   Provista, a proven leader in the ... purchasing power, today announced a new resource area on ... is the online home for case studies, articles ... news releases, slideshows and events. ... resources at their fingertips, viewers can also watch short ...
(Date:10/4/2017)... Oct. 4, 2017  According to the Centers for Disease Control and ... October . PhysicianOne Urgent Care is helping communities across Massachusetts ... , by offering no-cost* flu shots through the end of the ... certain health insurance regulations. ... time to get a flu shot is by the end of October, ...
Breaking Medicine Technology:
Cached News: